Clinical trials: Comparative Study
Healthy Volunteers
Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population
The purpose of this study is to evaluate the safety and efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine after the first and second treatment when used for facial augmentation in Asian population.
- Trial name
- NCT02565784
- Testing
- Restylane, Perlane
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Healthy Volunteers
Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application
Comparative PK study after single SC application of Afolia and the reference product (US Gonal-f®). Objective: To demonstrate equivalence within 80%-125% margin of the reference product for the area under the curve (AUC) of…
- Trial name
- NCT02459418
- Testing
- Afolia, US Gonal-f®
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Fertility Biotech AG
Healthy
Fasting Bioavailability Study of Lovastatin Tablets and Mevacor Tablets
The purpose of this study is to evaluate and compare the relative bioavailability and therefore the bioequivalence of a test formulation of lovastatin tablets to an equivalent dose of Mevacor® tablets after a single oral dose…
- Trial name
- NCT00685685
- Testing
- Lovastatin 40 mg tablets, Lovastatin (Mevacor®) 40 mg Tablets
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Healthy
A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of LY2963016 and US-approved Lantus®. The study involves four single injections; two doses of LY2963016 and two doses of US-approved Lantus®.
- Trial name
- NCT01688635
- Testing
- LY2963016, US Approved Lantus
- Where
- Singapore
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Epilepsy
Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate
Phase I, two-centre, open-label, randomized, gender-balanced, single-dose, laboratory blinded, two-period, two-sequence, crossover study in 2 groups of 20 healthy male and female subjects, to demonstrate the bioequivalence (BE)…
- Trial name
- NCT02284880
- Testing
- BIA 2-093
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Gastrointestinal Diseases
A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults
This is an open-label, randomized, single dose, two-sequence, two-period crossover study, separated by 7 days washout interval from the first study drug administration.
- Trial name
- NCT02446483
- Testing
- Idiazole 20mg DR tabs, PARIET 20 mg DR tabs
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Breast Cancer
Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer
The purpose of this pilot is to provide credible performance estimate information in order to conduct a subsequent pivotal reader study.
- Trial name
- NCT03491917
- Testing
- DBT plus S-View, FFDM alone
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fujifilm Medical Systems USA, Inc.
Healthy
Ursodiol 500 mg Tablets Under Fed Conditions
The objective of this study was to evaluate the comparative bioavailability between Ursodiol 500 mg Tablets (test) and Urso Forte™ 500 mg Tablets (reference)after a single-dose in healthy subjects under fed conditions.
- Trial name
- NCT00909753
- Testing
- Ursodiol, Urso Forte™
- Where
- Canada
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
Famciclovir 500 mg Tablets Under Non-Fasting Conditions
The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under non-fasting conditions.
- Trial name
- NCT00834444
- Testing
- Famciclovir 500 mg Tablets, Famvir® 500 mg Tablets
- Where
- 2 sites in United States, Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Bacterial Microflora Reduction
Comparative Study of Antimicrobial Effectiveness
Comparative Study of Antimicrobial Effectiveness Evaluation of 26 ml Project X, 5.1ml Project X and Prevantics® Maxi Swabstick following ASTM E1173 - Standard Test Method for Evaluation of Preoperative, Precatheterization, or…
- Trial name
- NCT03817580
- Testing
- Project X 26ml, Project X 5.1ml, Prevantics Maxi Swabstick
- Where
- Romania
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Professional Disposables International, Inc.
Hepatitis B
Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®
This study was a comparative, randomized, double-blind clinical study of the efficacy and safety of Sci-B-Vac® (10 μg dose) and the Engerix-B® (20 μg dose) vaccines in two parallel groups of hepatitis B-naive healthy adult…
- Trial name
- NCT04209400
- Testing
- Sci-B-Vac®, Engerix-B®
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Healthy
Pravastatin Sodium 80 mg Tablets Under Fasting Conditions
The objective of this study is to evaluate the comparative bioavailability between pravastatin sodium 80 mg tablets (Distributed by Teva Pharmaceuticals, USA) and Pravachol® 80 mg tablets (Bristol Myers Squibb, USA), after a…
- Trial name
- NCT00830258
- Testing
- Pravastatin sodium 80 mg tablets, Pravachol® 80 mg tablets
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Dental Crown, Prosthesis
Basic Study of Fabricating Biomorphic Crowns
The purpose of this study is to compare among different designs of the occlusal surface of artificial crowns, trying to determine a guidance of fabricating artificial crowns with better mimesis of the original tooth crown in…
- Trial name
- NCT02609178
- Testing
- FGP, AVR
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Air Force Military Medical University, China
Healthy
Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution
The purpose of this study is to compare subjective drug liking using the Drug Rating Questionnaire, subject version (DRQ-S), question 2 and pharmacokinetics of Vyvanse™ and ADDERALL XR® when administered as an oral solution.
- Trial name
- NCT00776555
- Testing
- Lisdexamfetamine Dimesylate, Racemic mixture of dextroamphetamine and lisdexamfetamine
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Shire
HIV Infections
Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men
This study is looking at 3 different types of enemas used before receptive anal intercourse in men who have sex with men (MSM). We are investigating whether the enemas cause any damage to the lining of the colon, how far up the…
- Trial name
- NCT00696618
- Testing
- Fleet Enema, tap water enema, Normosol-R enema
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects
The objective of this study is to determine bioequivalence between two different formulations of lamotrigine extended release tablets (one reference product and one generic product) in a healthy adult population, following a…
- Trial name
- NCT02821338
- Testing
- Lamotrigine Extended Release
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Healthy
Granisetron 1 mg Tablets Under Fasting Conditions
The objective of this study is to evaluate the comparative bioavailability between granisetron hydrochloride 1 mg tablets (Teva Pharmaceuticals USA) and Kytril® 1 mg tablets (Roche, USA), after a single-dose in health subjects…
- Trial name
- NCT00834717
- Testing
- Granisetron hydrochloride 1 mg tablets, Kytril® 1 mg tablets
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Meningococcal Disease, Meningococcal Meningitis
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
The primary objective of this study is to demonstrate the equivalence of rMenB+OMV NZ lot 1 to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum bactericidal activity (hSBA) geometric mean titers…
- Trial name
- NCT01423084
- Testing
- Serogroup B meningococcal vaccine
- Where
- 13 sites in Australia, Canada
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Novartis
Hypertension
A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.
- Trial name
- NCT01078376
- Testing
- Azilsartan medoxomil (TAK-491)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Fed Bioavailability Study of Lovastatin Tablets and Mevacor Tablets
The purpose of this study is to evaluate and compare the relative bioavailability and therefore the bioequivalence of a test formulation of Lovastatin tablets to an equivalent dose of Mevacor® tablets after a single oral dose…
- Trial name
- NCT00684723
- Testing
- Lovastatin 40 mg Tablets, Lovastatin (Mevacor®) 40 mg Tablets
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.